BACKGROUND: Aldosterone has been shown to substantially contribute to the accumulation of different types of collagen fibres and growth factors in the arterial wall, thus increasing wall thickness. A previous study showed reduction of increased common carotid intima-media thickness (IMT) in patients with primary aldosteronism 1 year after adrenalectomy. Our study in patients with primary aldosteronism was aimed at comparing the long-term effect of adrenalectomy vs. spironolactone therapy on common carotid IMT regression. METHOD: Forty-two patients with confirmed primary aldosteronism (21 with aldosterone-producing adenoma treated by unilateral laparoscopic adrenalectomy, 21 treated with spironolactone) were investigated by carotid ultrasound at baseline and 1 and 6 years after the specific treatment. RESULTS: There was a decrease in common carotid IMT from 0.956 ± 0.140 to 0.900 ± 0.127 mm (-5.9%; P < 0.05) at 1 year and to 0.866 ± 0.130 mm (-9.4%; P < 0.01) at 6 years after adrenalectomy; in the spironolactone group, common carotid IMT decreased from 0.917 ± 0.151 to 0.900 ± 0.165 mm (-1.8%; NS) at 1 year and to 0.854 ± 0.176 mm (-6.8%; P < 0.01) at 6 years of treatment. The magnitude of improvement at 1 year was significantly higher (by 70%; P < 0.05) in the adrenalectomy group; however, the difference (by 27%) became nonsignificant at 6 years. Comparing the adrenalectomy and spironolactone groups, there was no significant difference in blood pressure decrease after treatment. CONCLUSION: In the long term, spironolactone therapy in patients with primary aldosteronism had significant effect on regression of IMT, which was comparable to surgical treatment in patients with unilateral forms of primary aldosteronism.

3rd Department of Medicine b1st Department of Surgery cDepartment of Urology Centre for Hypertension General University Hospital and 1st Faculty of Medicine Charles University Prague dDepartment of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

See more in PubMed

Štrauch B, Zelinka T, Hampf M, Bernhardt R, Widimský J., Jr Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17:349–352. PubMed

Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies – a review of the current literature. Horm Metab Res 2012; 44:157–162. PubMed

Kim SH, Ahn JH, Hong HC, Choi HY, Kim YJ, Kim NH, et al. Changes in the clinical manifestations of primary aldosteronism. Korean J Intern Med 2014; 29:217–225. PubMed PMC

Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243–1248. PubMed

Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62:331–336. PubMed

Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80–85. PubMed

Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60:618–624. PubMed

Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res 2012; 44:181–187. PubMed

Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010; 28:2120–2126. PubMed

Widimský J, Jr, Štrauch B, Petrák O, Rosa J, Šomlóová Z, Zelinka T, Holaj R. Vascular disturbances in primary aldosteronism: clinical evidence. Kidney Blood Press Res 2012; 35:529–533. PubMed

Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039–1045. PubMed

Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232–238. PubMed

Štrauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimský J., Jr Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19:909–914. PubMed

Holaj R, Zelinka T, Wichterle D, Petrák O, Štrauch B, Widimský J., Jr Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25:1451–1457. PubMed

Štrauch B, Petrák O, Zelinka T, Wichterle D, Holaj R, Kasalický M, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008; 21:1086–1092. PubMed

Lin YH, Lin LY, Chen A, Wu XM, Lee JK, Su TC, et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis 2012; 221:154–159. PubMed

Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50:911–918. PubMed

Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131:105–108. PubMed

Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg 2002; 89:1587–1593. PubMed

Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007; 25:1433–1442. PubMed

Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24:737–745. PubMed

Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045–1050. PubMed

Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74:1399–1406. PubMed

Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839–845. PubMed

Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006; 37:1933–1940. PubMed

Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1380–1387. PubMed PMC

Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004; 109:IV22–IV30. PubMed

Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970:89–100. PubMed

Funder JW, Pearce PT, Smith R, Campbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989; 125:2224–2226. PubMed

Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 1998; 273:15249–15256. PubMed

Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28:1002–1006. PubMed

Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47:312–318. PubMed

Callera GE, Montezano AC, Yogi A, Tostes AC, He Y, Schiffrin EL, Touyz RM. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46:1032–1038. PubMed

Callera GE, Yogi A, Briones AM, Montezano AC, He Y, Tostes RC, et al. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc Res 2011; 91:720–731. PubMed

Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60:820–825. PubMed

Mulatero P, Bertello C, Rossato D, Mengozzi G, Milan A, Garrone C, et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008; 93:1366–1371. PubMed

Štrauch B, Petrák O, Zelinka T, Rosa J, Šomlóová Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31:2455–2461. PubMed

Kornet L, Lambregts J, Hoeks AP, Reneman RS. Differences in near-wall shear rate in the carotid artery within subjects are associated with different intima-media thicknesses. Arterioscler Thromb Vasc Biol 1998; 18:1877–1884. PubMed

Irace C, Cortese C, Fiaschi E, Carallo C, Farinaro E, Gnasso A. Wall shear stress is associated with intima-media thickness and carotid atherosclerosis in subjects at low coronary heart disease risk. Stroke 2004; 35:464–468. PubMed

Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53:605–610. PubMed

Štrauch B, Widimský J, Šindelka G, Škrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 2003; 52:503–506. PubMed

Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan EDJr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877–885. PubMed

Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459–467. PubMed

Adrenal Venous Sampling Could Be Omitted before Surgery in Patients with Conn's Adenoma Confirmed by Computed Tomography and Higher Normal Aldosterone Concentration after Saline Infusion Test

Should All Patients with Resistant Hypertension Receive Spironolactone?